Department of Medicine, University of California San Francisco, 94115, USA.
J Cancer Surviv. 2010 Sep;4(3):247-55. doi: 10.1007/s11764-010-0130-1. Epub 2010 Jul 4.
As the number of breast cancer survivors increases, the long term consequences of breast cancer treatment are gaining attention. Sexual dysfunction is a common complaint amongst breast cancer survivors, and there are few evidence based recommendations and even fewer well designed clinical trials to establish what treatments are safe or effective in this patient population.
We conducted a PubMed search for articles published between 1995-2009 containing the terms breast cancer, sexual dysfunction, libido, vaginal dryness, testosterone, and vaginal estrogen. We initially reviewed articles focusing exclusively on sexual issues in breast cancer patients. Given the paucity of clinical trials addressing sexual issues in breast cancer patients, we also included studies evaluating both hormone and non-hormone based interventions for sexual dysfunction in post-menopausal women in general.
Among breast cancer survivors, vaginal dryness and loss of libido represent some of the most challenging long term side effects of breast cancer treatment. In the general post-menopausal population, topical preparations of estrogens and testosterone both appear to improve sexual function; however there are conflicting reports about the efficacy and safety of these interventions in women with a history of breast cancer, and further research is warranted.
随着乳腺癌幸存者人数的增加,乳腺癌治疗的长期后果引起了人们的关注。性功能障碍是乳腺癌幸存者常见的抱怨,针对这一患者群体,几乎没有基于证据的推荐意见,甚至几乎没有精心设计的临床试验来确定哪些治疗方法是安全或有效的。
我们在 PubMed 上搜索了 1995 年至 2009 年间发表的包含“乳腺癌”、“性功能障碍”、“性欲”、“阴道干燥”、“睾酮”和“阴道雌激素”等术语的文章。我们最初只审查了专门关注乳腺癌患者性功能问题的文章。鉴于针对乳腺癌患者性功能问题的临床试验寥寥无几,我们还包括了评估一般绝经后妇女中基于激素和非激素干预措施治疗性功能障碍的研究。
在乳腺癌幸存者中,阴道干燥和性欲丧失是乳腺癌治疗的一些最具挑战性的长期副作用。在一般绝经后人群中,雌激素和睾酮的局部制剂似乎都能改善性功能;然而,关于这些干预措施在有乳腺癌病史的女性中的疗效和安全性的报告相互矛盾,需要进一步研究。